var data={"title":"Isosorbide mononitrate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Isosorbide mononitrate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6411?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=isosorbide-mononitrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Isosorbide mononitrate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185079\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Imdur [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185080\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-ISMN;</li>\n      <li>Imdur;</li>\n      <li>PMS-ISMN;</li>\n      <li>PRO-ISMN</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185126\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185083\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Angina pectoris:</b> Oral: <b>Note: </b>Tolerance to nitrate effects develops with chronic exposure. Dose escalation does not overcome this effect. Tolerance can only be overcome by short periods of nitrate absence from the body. Recommended twice daily dosage regimens incorporate this interval. Short periods of nitrate withdrawal may help minimize tolerance. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Immediate release: </i>20 mg twice daily with the 2 doses given 7 hours apart (eg, 8 AM and 3 PM) to decrease tolerance development; patients with small stature may initiate therapy with 5 mg twice daily and titrate to at least 10 mg twice daily in first 2 to 3 days of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Extended release:</i> Initial: 30 to 60 mg once daily in the morning; may titrate after several days to 120 mg once daily; rarely, 240 mg once daily may be required</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185084\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; initiate with lowest recommended dose. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185085\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Supplemental dose is not necessary. Dose after dialysis (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous ambulatory peritoneal dialysis: Supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11593043\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185059\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imdur: 30 mg [DSC], 60 mg [DSC], 120 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 60 mg, 120 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185044\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185063\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Do not administer around-the-clock. Immediate release tablet should be scheduled twice daily with doses 7 hours apart (8 AM and 3 PM); administer extended release tablet once daily in the morning upon rising with a half-glassful of fluid. Do not chew or crush extended release tablets; may be divided in half. Due to insoluble matrix embedding, extended release tablets that are scored may be split (Gunasekara 1999). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185062\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Angina pectoris:</b> Treatment (immediate-release only) and prevention of angina pectoris caused by coronary artery disease.  <b>Note: </b>The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185134\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Imdur may be confused with Imuran, Inderal LA, K-Dur</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Monoket may be confused with Monopril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Vasodilators (isosorbide mononitrate) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older with a history of syncope due to its potential to exacerbate episodes of syncope (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185051\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (13% to 35%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris (&le;2%), flushing (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;4%), fatigue (&le;4%), pain (&le;4%), emotional lability (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&le;2%), skin rash (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;3%), abdominal pain (&le;2%), diarrhea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory infection (&le;4%), increased cough (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Amblyopia, anorexia, anxiety, asthma, back pain, bradycardia, cardiac arrhythmia, cerebrovascular accident, depression, diaphoresis, dysgeusia, dyspepsia, dyspnea, edema, hypertension, hypotension, increased thirst, insomnia, lack of concentration, methemoglobinemia (rare; overdose), muscle cramps, myocardial infarction, neck pain, nervousness, nightmares, orthostatic hypotension, pallor, palpitations, paresthesia, prostatic disease, restlessness, sinusitis, tachycardia, tinnitus, tremor, vertigo, vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185066\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to isosorbide mononitrate, other nitrates or nitrites, or any component of the formulation; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or vardenafil) or riociguat.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Acute circulatory failure associated with marked hypotension (shock and states of collapse); postural hypotension; myocardial insufficiency due to obstruction (eg, in the presence of aortic or mitral stenosis or of constrictive pericarditis); increased intracranial pressure; severe anemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185048\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Severe hypotension, particularly with upright posture, may occur with even small doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intracranial pressure increased: Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Not recommended for use in patients with acute myocardial infarction (MI) or heart failure (has not been studied). Use with caution in volume depletion and moderate hypotension, and with extreme caution with inferior wall MI and suspected right ventricular infarctions. The Canadian labeling contraindicates use in acute circulatory failure associated with marked hypotension, postural hypotension, and myocardial insufficiency due to obstruction (eg, in the presence of aortic or mitral stenosis or of constrictive pericarditis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (Gersh 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (O&rsquo;Connor 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage forms related issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extended-release tablets: Empty matrix &quot;ghosts&quot; (tablets) may pass in patients via colostomy or in the stool; this is of no concern.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Extended-release: Not intended for the immediate relief of acute attacks of angina pectoris.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tolerance: Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185121\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185053\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8581&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185055\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11593066\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Nitric oxide donors, such as isosorbide, have been evaluated for pre-eclampsia and cervical ripening; isosorbide mononitrate use in these conditions is not currently recommended (Kalidindi 2012; Ramirez 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20681079\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if isosorbide mononitrate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering isosorbide mononitrate to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185057\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185047\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitroglycerin and other nitrates form free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3&rsquo;5&rsquo; monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185065\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 30 to 45 minutes (Thadani 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Immediate release: &ge;6 hours (Thadani 1987); Extended release: &ge;12 to 24 hours (Anderson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 5 to 6 hours (Thadani 1987) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Predominantly urine (2% as unchanged drug); feces (1%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185068\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Isosorbide Mononitrate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $111.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $142.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $293.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Isosorbide Mononitrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $50.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $73.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185069\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AngiFix (BD);</li>\n      <li>Angifree SR (LK);</li>\n      <li>Angisor (BD);</li>\n      <li>Angistad (PH);</li>\n      <li>Angitrate (ZA);</li>\n      <li>Apo-ISMN (HK);</li>\n      <li>Cardismo (ID);</li>\n      <li>Cardisorb (HU);</li>\n      <li>Cardoxx (HR);</li>\n      <li>Cincordil (BR);</li>\n      <li>Conpin (DE);</li>\n      <li>Corangin (CH, NZ);</li>\n      <li>Corangin SR (TW);</li>\n      <li>Coronur (ES);</li>\n      <li>Coronur Retard (ES);</li>\n      <li>Coxine (TW);</li>\n      <li>Coxine SR (TW);</li>\n      <li>Danlixin (CN);</li>\n      <li>Duride (AU, NZ, TW);</li>\n      <li>Effox (PL);</li>\n      <li>Elan (IT);</li>\n      <li>Elantan (AE, AT, CR, CZ, DE, DO, EC, GT, HN, ID, IE, JO, KR, LU, MX, MY, NI, PA, PE, PH, PK, SG, SV, VE);</li>\n      <li>Elantan LA (MY);</li>\n      <li>Elantan Long (CZ, DE, LT, MY, PH, SG);</li>\n      <li>Elantan SR (KW);</li>\n      <li>Elonton SR (KR);</li>\n      <li>Imdex (HK, TH);</li>\n      <li>Imdex CR (MY, SG);</li>\n      <li>Imdur (AE, BF, BH, BJ, CI, CN, CY, DK, EE, ET, GB, GH, GM, GN, HK, ID, IE, KE, KW, LK, LR, LU, LV, MA, ML, MR, MT, MU, MW, NE, NG, PH, PT, SA, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, VN, ZM, ZW);</li>\n      <li>Imdur 60 (MX, TW);</li>\n      <li>Imdur Durules (AU, KR);</li>\n      <li>Imidu (VN);</li>\n      <li>Imtrate (NZ);</li>\n      <li>Ismexin (FI);</li>\n      <li>ISMN (AT, DE);</li>\n      <li>ISMN AL (HU);</li>\n      <li>ISMN Genericon (HR);</li>\n      <li>ISMN Pharmavit (HU);</li>\n      <li>Ismo (AE, BH, LU, QA, SA);</li>\n      <li>ISMO (CL, DK, EG, GB, IE, IS, IT, NL, SE);</li>\n      <li>Ismo 20 (BB, BM, BS, BZ, GY, IN, JM, MY, NZ, PR, SR, TH, TT, TW, ZA);</li>\n      <li>Ismo-20 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ismodin (PH);</li>\n      <li>Ismox (FI);</li>\n      <li>Isobid (KR);</li>\n      <li>Isocard (HR);</li>\n      <li>Isolan (AR);</li>\n      <li>Isomel (IE);</li>\n      <li>Isomon (GR);</li>\n      <li>Isomonat (AT, CZ);</li>\n      <li>Isomonit (AU, DE, IE, LU, PL);</li>\n      <li>Isomonit Retard (VN);</li>\n      <li>Isonate (PH);</li>\n      <li>Isopen-20 (TH);</li>\n      <li>Isorat (TR);</li>\n      <li>Isosorbide (CY, HR);</li>\n      <li>Isospan SR (HU);</li>\n      <li>Isotril ER (KR);</li>\n      <li>MNI (PY);</li>\n      <li>Monicor (FR, LK);</li>\n      <li>Monis (CO);</li>\n      <li>Monis-XR (PH);</li>\n      <li>Monit (BD);</li>\n      <li>Monit 20 (IN);</li>\n      <li>Mono Corax (DE);</li>\n      <li>Mono Corax Retard (DE);</li>\n      <li>Mono Mack (CY, HU, LU, MX);</li>\n      <li>Mono-Mack (CZ);</li>\n      <li>Mono-Sanorania (DE);</li>\n      <li>Monobide (EC);</li>\n      <li>Monoclair (DE);</li>\n      <li>Monocord 40 (IL);</li>\n      <li>Monocord 50 SR (IL);</li>\n      <li>Monodur Durules (AU);</li>\n      <li>Monoket (IT, NO, PY, SE, UY);</li>\n      <li>Monoket OD (SE);</li>\n      <li>Monoket Retard (AT, IT);</li>\n      <li>Monolong (DE);</li>\n      <li>Monolong 40 (IL);</li>\n      <li>Monolong 60 (IL);</li>\n      <li>Mononit (PE, PL);</li>\n      <li>Mononit 20 (IL);</li>\n      <li>Monopront (FI);</li>\n      <li>Monorem (TR);</li>\n      <li>Monosan (RU, UA);</li>\n      <li>Monosorb (TH);</li>\n      <li>Monosorbitrate (IN);</li>\n      <li>Monosordil (GR);</li>\n      <li>Monotab (SK);</li>\n      <li>Monotrate (IN);</li>\n      <li>Monotrate OD (LK);</li>\n      <li>Montra (PH);</li>\n      <li>Nitramin (GR);</li>\n      <li>Oilkord Retard (UA);</li>\n      <li>Olicard (BG, HR, HU, RO);</li>\n      <li>Pentacard (BE, ID);</li>\n      <li>Rangin (HU);</li>\n      <li>Solotrate (TH);</li>\n      <li>Solotrate SR (LK);</li>\n      <li>Sorbimon (HU);</li>\n      <li>Sorbinate SR (TH);</li>\n      <li>Sormon (IE);</li>\n      <li>Trangina XL (MT);</li>\n      <li>Unicard (BD);</li>\n      <li>Uniket (ES);</li>\n      <li>Vasotrate (IN, PH);</li>\n      <li>Vasotrate-60 OD (PH);</li>\n      <li>Vasotrate-OD (SG);</li>\n      <li>Vasotrol (VN);</li>\n      <li>Xismox XL (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):e1-e157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/17692738/pubmed\" target=\"_blank\" id=\"17692738\">17692738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):273-82. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/9935041/pubmed\" target=\"_blank\" id=\"9935041\">9935041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty JT, &ldquo;Hemodynamic Attenuation and the Nitrate Dose-Free Interval: Alternative Dosing Strategies for Transdermal Nitroglycerin,&rdquo; <i>Am J Cardiol</i>, 1985, 56(17):321-71. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3895880/pubmed\" target=\"_blank\" id=\"3895880\">3895880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gunasekara NS, Noble S, Isosorbide 5-Mononitrate - a review of a sustained-release formulation (Imdur) in stable angina pectoris. <i>Drugs</i>. 1999;57(2):261-277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/10188765/pubmed\" target=\"_blank\" id=\"10188765\">10188765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt SA, Baker DW, Chin MH, et al, &ldquo;ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure),&rdquo; <i>J Am Coll Cardiol</i>, 2001, 38(7):2101-13. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11738322/pubmed\" target=\"_blank\" id=\"11738322\">11738322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imdur (isosorbide mononitrate) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isosorbide mononitrate tablets [prescribing information]. Parsippany, NJ: Actavis Pharma Inc.; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isosorbide mononitrate extended-release tablets [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals USA Inc.; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalidindi M, Velauthar L, Khan K, et al, &quot;The Role of Nitrates in the Prevention of Preeclampsia: An Update,&quot; <i>Curr Opin Obstet Gynecol</i>, 2012, 24(6):361-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/23108288/pubmed\" target=\"_blank\" id=\"23108288\">23108288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Connor RE, Brady W, Brooks SC, et al, &quot;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Care Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):787-817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/20956226/pubmed\" target=\"_blank\" id=\"20956226\">20956226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JO, &ldquo;Eccentric Dosing With Isosorbide-5-Mononitrate in Angina Pectoris,&rdquo; <i>Am J Cardiol</i>, 1993, 72(12):871-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8213541/pubmed\" target=\"_blank\" id=\"8213541\">8213541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JO, Fanell B, Lahey KA, et al, &ldquo;Effect of Intervals Between Doses on the Development to Tolerance to Isosorbide Dinitrate,&rdquo; <i>N Engl J Med</i>, 1987, 316(23):1440-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3574424/pubmed\" target=\"_blank\" id=\"3574424\">3574424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramirez MM, &quot;Labor Induction: A Review of Current Methods,&quot; <i>Obstet Gynecol Clin North Am</i>, 2011, 38(2):215-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/21575797/pubmed\" target=\"_blank\" id=\"21575797\">21575797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. [published correction appears in  <i>Neurol Clin</i>. 2008;26(3):xvii].  <i>Neurol Clin</i>. 2008;26(2):521-41, x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/18514825/pubmed\" target=\"_blank\" id=\"18514825\">18514825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thadani U, Prasad R, Hamilton SF, et al, &ldquo;Isosorbide-5-Mononitrate in Angina Pectoris: Plasma Concentrations and Duration of Effects After Acute Therapy,&rdquo; <i>Clin Pharmacol Ther</i>, 1987, 42(1):58-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3595067/pubmed\" target=\"_blank\" id=\"3595067\">3595067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Villaneuva C, Minana J, Ortiz J, et al, &ldquo;Endoscopic Litigation Compared With Combined Treatment With Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding,&rdquo; <i>N Engl J Med</i>, 2001, 345(9):647-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11547718/pubmed\" target=\"_blank\" id=\"11547718\">11547718</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8581 Version 198.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F185079\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F185080\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F185126\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F185083\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F185084\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F185085\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F11593043\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185059\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F185044\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F185063\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F185062\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F185134\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185051\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185066\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185048\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F185121\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185053\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F185055\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11593066\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20681079\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F185057\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F185047\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F185065\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F185068\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F185069\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8581|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=isosorbide-mononitrate-patient-drug-information\" class=\"drug drug_patient\">Isosorbide mononitrate: Patient drug information</a></li></ul></div></div>","javascript":null}